Sulforaphane (DB12422): A Comprehensive Monograph on its Chemistry, Pharmacology, and Therapeutic Potential

Executive Summary

Sulforaphane (SFN) is a naturally occurring isothiocyanate phytochemical derived from cruciferous vegetables, most notably broccoli and broccoli sprouts. As an investigational small molecule, SFN has garnered significant scientific interest due to its pleiotropic biological activities and potential therapeutic applications across a spectrum of chronic diseases. This report provides a comprehensive analysis of SFN, synthesizing current knowledge on its chemistry, pharmacology, clinical evidence, safety profile, and regulatory landscape.

The therapeutic potential of SFN is rooted in two primary, complementary mechanisms of action. Its most well-characterized activity is as a potent indirect antioxidant through the activation of the Nuclear factor erythroid 2-related factor 2 (Nrf2) transcriptional pathway. By modulating the Nrf2-Keap1 signaling axis, SFN upregulates a vast array of cytoprotective genes, including phase II detoxification and antioxidant enzymes, thereby fortifying cellular defenses against oxidative stress and inflammation. Concurrently, SFN functions as a histone deacetylase (HDAC) inhibitor, an epigenetic mechanism that can restore the expression of silenced tumor suppressor genes and modulate protein stability, which is particularly relevant to its anticancer effects.

Clinical investigations have primarily focused on two promising areas: oncology and neurodevelopmental disorders. In oncology, SFN is being evaluated as a chemopreventive agent, with evidence suggesting it may slow the progression of early-stage prostate and breast cancers. In the context of Autism Spectrum Disorder (ASD), a landmark study demonstrated significant improvements in behavioral and social metrics in young men, although subsequent trials in younger pediatric populations have yielded inconsistent results, suggesting a potential age-dependent therapeutic window.

A critical determinant of SFN's clinical efficacy is its bioavailability, which is profoundly influenced by the enzymatic conversion of its inactive precursor, glucoraphanin, by the myrosinase enzyme. This "Myrosinase Gap" explains the significant variability in SFN absorption from different dietary sources and supplemental formulations, representing the central challenge for consistent therapeutic delivery.

At clinically relevant doses, SFN exhibits a favorable safety profile, with adverse events being predominantly mild and gastrointestinal in nature. However, its potent bioactivity is underscored by a significant potential for drug-drug interactions, primarily through the modulation of cytochrome P450 enzymes, necessitating clinical caution. SFN occupies a unique position in the regulatory sphere, existing concurrently as a widely available, loosely regulated dietary supplement and as a stabilized formulation with FDA Orphan Drug Designation for the treatment of subarachnoid hemorrhage. This regulatory duality highlights both the compound's therapeutic promise and the market's challenges in ensuring product quality and efficacy. Future research must prioritize the development of standardized, bioavailable formulations and well-designed clinical trials to fully elucidate the therapeutic role of this compelling phytochemical.

Compound Profile: Identification and Physicochemical Properties

A precise and unambiguous characterization of sulforaphane is fundamental to interpreting the extensive body of research associated with it. This section details its nomenclature, chemical identifiers, molecular structure, and key physicochemical properties.

Nomenclature and Chemical Identifiers

Sulforaphane is known by a variety of names and is cataloged across numerous chemical and biological databases. A significant point of potential confusion arises from the existence of distinct CAS (Chemical Abstracts Service) numbers for the naturally occurring, biologically active stereoisomer and the synthetically derived racemic mixture. The naturally occurring form is the L-isomer, which corresponds to the (R)-configuration at the chiral sulfur atom, designated as (R)-Sulforaphane.[1] Research or products utilizing the racemic mixture may exhibit different pharmacological profiles, making the distinction critical for reproducibility and clinical relevance. The primary identifiers for sulforaphane are consolidated in Table 1.

Table 1: Chemical and Database Identifiers for Sulforaphane

Identifier Type	Value	Source(s)
Primary Name	Sulforaphane	3
DrugBank ID	DB12422	3
CAS Number (R-isomer)	142825-10-3	1
CAS Number (racemic)	4478-93-7	3
IUPAC Name	1-isothiocyanato-4-methylsulfinylbutane	3
Stereospecific IUPAC Name	1-isothiocyanato-4--butane	1
Synonyms	L-SFN, (R)-SFN, sulforafan, sulphoraphane, BroccoPhane, Detoxophane	1
PubChem CID	5350	7
ChEBI ID	CHEBI:47807	3
ChEMBL ID	CHEMBL48802	3
HMDB ID	HMDB0005792	3
InChIKey (R-isomer)	SUVMJBTUFCVSAD-SNVBAGLBSA-N	1
InChIKey (racemic)	SUVMJBTUFCVSAD-UHFFFAOYSA-N	3

Molecular Structure and Chemical Classification

Sulforaphane is an organosulfur compound defined by its dual chemical functionalities. Structurally, it is an isothiocyanate characterized by a −N=C=S functional group, with a 4-(methylsulfinyl)butyl group attached to the nitrogen atom.[3] This chemical architecture places it within the broader class of sulfoxides, which are compounds containing a sulfoxide functional group,

R−S(=O)−R′.[4]

• Chemical Formula: C6​H11​NOS2​ [1]
• Structural Representations:
• SMILES (racemic): CS(=O)CCCCN=C=S [3]
• SMILES ((R)-isomer): C(CCCCN=C=S)=O [1]
• InChI ((R)-isomer): InChI=1S/C6H11NOS2/c1-10(8)5-3-2-4-7-6-9/h2-5H2,1H3/t10-/m1/s1 [1]

The electrophilic nature of the isothiocyanate group is central to its primary mechanism of action, allowing it to react with nucleophilic sulfhydryl groups on proteins such as Keap1. The sulfoxide group introduces chirality to the molecule, which is critical for its biological specificity.

Physicochemical and Experimental Properties

The physical and chemical properties of sulforaphane dictate its stability, solubility, and behavior in biological assays and formulations.

• Molecular Weight: The average molecular weight is approximately 177.3 g/mol, with a precise monoisotopic mass of 177.02820632 Da.[3]
• Physical Description: It has been described as both a solid powder and a colorless to yellow-brown oil, suggesting that its physical state may depend on purity, isomeric composition, and ambient conditions.[3]
• Solubility: Sulforaphane exhibits good solubility in organic solvents, a property essential for its use in research and for formulation development. Representative solubility data includes:
• DMSO: 15 mg/ml [1]
• Ethanol: 20 mg/ml [1]
• DMF: 1 mg/ml [1]
• PBS (pH 7.2): 10 mg/ml [1]
• Stability and Storage: Sulforaphane is sensitive to degradation and requires specific storage conditions to maintain its integrity. For long-term storage (months to years), temperatures of -20°C to -80°C are recommended.[1] It is stable for at least two years under these conditions.[2] It should be stored in a dry, dark environment.[5]
• Safety and Handling: According to the Globally Harmonized System (GHS) of Classification and Labelling of Chemicals, sulforaphane is classified as a hazardous substance. It carries warnings for being harmful if swallowed (H302) or inhaled (H332), and for causing skin irritation (H315), serious eye irritation (H319), and respiratory irritation (H335).[3] Appropriate personal protective equipment and handling procedures are required when working with the pure compound.

Biological Origin and Bioavailability

The therapeutic efficacy of sulforaphane is inextricably linked to its biological origin and the complex biochemical processes that govern its formation and absorption. Understanding these factors is paramount, as they represent the most significant variables controlling the delivery of the active compound to target tissues.

Natural Sources and Precursor Chemistry

Sulforaphane is not synthesized directly by plants. Instead, it is derived from an inactive precursor, the glucosinolate known as glucoraphanin.[1] Glucosinolates are a class of sulfur-containing secondary metabolites characteristic of the plant order

Brassicales. Glucoraphanin is found in high concentrations in a variety of cruciferous vegetables, which serve as the primary dietary sources of sulforaphane. These include:

• Broccoli and broccoli sprouts
• Brussels sprouts
• Cauliflower
• Kale
• Cabbage (red and white varieties)
• Bok choy
• Watercress
• Arugula [8]

Among these, broccoli sprouts are particularly noteworthy, containing levels of glucoraphanin that can be 20 to 50 times higher than those found in mature broccoli heads, making them an exceptionally potent source.[9]

The Myrosinase Enzyme: A Critical Factor in Bioactivation

The conversion of the inert glucoraphanin into biologically active sulforaphane is an enzymatic process catalyzed by myrosinase (thioglucoside glucohydrolase).[5] In the intact plant, glucoraphanin and myrosinase are physically segregated in different cellular compartments. When the plant tissue is damaged—through mechanical actions such as chopping, cutting, or chewing—the compartments are ruptured, allowing the enzyme to come into contact with its substrate and initiate the hydrolysis reaction that yields sulforaphane.[8]

This enzymatic conversion is highly sensitive to heat. Myrosinase is rapidly denatured at temperatures exceeding 140°C (284°F), and even milder cooking methods like boiling or microwaving can significantly reduce its activity.[9] Consequently, the potential yield of sulforaphane from cooked cruciferous vegetables is substantially lower than from their raw counterparts. For instance, one study found that raw broccoli contained ten times more sulforaphane than cooked broccoli.[9] To maximize sulforaphane formation, food preparation techniques can be optimized. Lightly steaming vegetables for one to three minutes is considered the best cooking method to preserve myrosinase activity.[9] Another effective strategy is the "hack and hold" method, where vegetables are chopped and allowed to rest for 30 to 40 minutes before cooking. This rest period allows the myrosinase enzyme to complete the conversion to sulforaphane before heat is applied.[8]

Comparative Bioavailability: Dietary vs. Supplemental Forms

The critical role of myrosinase activity creates a significant challenge for delivering consistent and effective doses of sulforaphane, a phenomenon that can be termed the "Myrosinase Gap." This gap represents the difference between the amount of precursor (glucoraphanin) present and the amount of active sulforaphane that is actually formed and absorbed. This issue is central to the disparity in bioavailability observed between different dietary forms and supplements.

When myrosinase is inactivated by cooking, the conversion of glucoraphanin to sulforaphane becomes dependent on the myrosinase activity of the human gut microbiota.[14] This process is highly variable among individuals and is generally inefficient, resulting in low and unpredictable bioavailability.[15] This same challenge affects many commercial dietary supplements, which are often formulated with glucoraphanin-rich extracts where the native myrosinase has been denatured during processing. Such supplements deliver the precursor but lack the necessary enzyme for efficient conversion, leading to poor clinical translation of preclinical promise.[16]

In contrast, consumption of raw cruciferous vegetables, particularly broccoli sprouts, provides both the substrate and the active enzyme, leading to significantly higher bioavailability. Clinical studies have demonstrated that sulforaphane absorption from fresh broccoli sprouts can be three to seven times higher than from supplements containing only glucoraphanin or even those with added myrosinase.[16] This suggests that the whole food matrix, perhaps through factors like fiber content that modulate gut transit time, may further enhance absorption.[16]

To bridge the Myrosinase Gap, advanced supplement formulations have been developed. These products aim to increase bioavailability by co-formulating glucoraphanin with a source of active myrosinase, such as mustard seed powder, or by utilizing specialized extraction and stabilization processes to preserve the plant's endogenous enzyme.[15] Encapsulation techniques can also be employed to protect the enzyme and substrate from degradation in the stomach, allowing for release and conversion in the small intestine.[15] The ultimate success of any sulforaphane-based intervention, whether dietary or supplemental, hinges on effectively overcoming this biochemical delivery challenge to ensure a reliable and therapeutically relevant dose of the active compound is absorbed.

Core Pharmacological Mechanisms of Action

Sulforaphane exerts its diverse biological effects through a multi-pronged pharmacological strategy, engaging two principal and powerful molecular pathways. Its ability to act as both a master regulator of cellular defense and a targeted epigenetic modulator explains its broad therapeutic potential in conditions ranging from cancer to neurodevelopmental disorders.

Primary Mechanism: Activation of the Nrf2-Keap1 Antioxidant Response Pathway

The most extensively documented mechanism of action for sulforaphane is its potent activation of the Nrf2-Keap1 pathway, which governs the expression of a wide array of cytoprotective genes.[19] Sulforaphane functions as an indirect antioxidant, not by directly scavenging free radicals, but by amplifying the body's endogenous antioxidant and detoxification systems.

Under homeostatic conditions, the transcription factor Nrf2 is held inactive in the cytoplasm through its association with a repressor protein, Keap1.[19] Keap1 acts as a sensor for oxidative and electrophilic stress and, in the absence of such stressors, continuously targets Nrf2 for ubiquitination and subsequent degradation by the proteasome, thereby maintaining low basal levels of Nrf2 activity.[20]

Sulforaphane, being an electrophilic isothiocyanate, directly interacts with this system. It covalently modifies highly reactive cysteine residues on the Keap1 protein.[1] This modification induces a conformational change in Keap1, disrupting its ability to bind Nrf2 and preventing its degradation.[2] The stabilized Nrf2 is then free to translocate into the cell nucleus.

Once in the nucleus, Nrf2 dimerizes with small Maf proteins and binds to specific DNA sequences known as Antioxidant Response Elements (AREs), located in the promoter regions of its target genes.[19] This binding event initiates the coordinated transcription of hundreds of genes that form the core of the cellular defense system. Key classes of Nrf2-inducible genes include:

• Phase II Detoxification Enzymes: These enzymes, such as NAD(P)H:quinone oxidoreductase 1 (NQO1) and glutathione S-transferases (GSTs), are critical for neutralizing and facilitating the excretion of carcinogens, xenobiotics, and harmful reactive oxygen species.[5]
• Antioxidant Proteins: This includes enzymes responsible for the synthesis and regeneration of glutathione (GSH), the most abundant endogenous antioxidant, as well as other protective enzymes like heme oxygenase-1 (HO-1).[5]

Due to its high bioavailability and potent induction capacity, sulforaphane is considered a more powerful Nrf2 activator than many other well-known phytochemicals, such as curcumin and resveratrol.[19]

Secondary Mechanism: Inhibition of Histone Deacetylase (HDAC) Activity

In addition to its effects on the Nrf2 pathway, sulforaphane functions as an inhibitor of histone deacetylase (HDAC) enzymes. This epigenetic mechanism provides a distinct and complementary mode of action, particularly relevant to its anticancer properties.[3]

HDACs are a class of enzymes that remove acetyl groups from lysine residues on histones and other proteins. In cancer, HDACs are often overexpressed, leading to the deacetylation of histones, chromatin condensation, and the transcriptional silencing of critical tumor suppressor genes.[23] By inhibiting HDAC activity, sulforaphane promotes histone hyperacetylation, which leads to a more open chromatin structure and can facilitate the re-expression of these silenced genes, such as the cell cycle inhibitor

p21WAF1.[22]

Research has revealed a highly specific and drug-like mechanism within this class of activity. In prostate cancer cells, sulforaphane was found to selectively inhibit the activity of HDAC6, a predominantly cytoplasmic deacetylase.[23] One of the key non-histone substrates of HDAC6 is the molecular chaperone Heat Shock Protein 90 (HSP90). HSP90 is essential for the stability and function of numerous client proteins involved in cancer progression, including the Androgen Receptor (AR).[23]

The mechanism proceeds as follows:

1. Sulforaphane inhibits HDAC6 enzymatic activity.
2. This leads to the hyperacetylation of HSP90.
3. Hyperacetylated HSP90 is unable to properly chaperone the Androgen Receptor.
4. The association between HSP90 and AR is disrupted, leading to the destabilization and subsequent proteasomal degradation of the AR protein.[23]

By dismantling the AR signaling axis, sulforaphane provides a targeted mechanism to impair the growth of hormone-sensitive prostate cancer. This dual-mechanism profile—combining broad cytoprotection via Nrf2 with targeted epigenetic and protein regulation via HDAC inhibition—makes sulforaphane a uniquely versatile therapeutic agent. The dominant mechanism may be context-dependent, with Nrf2 activation being paramount in preventative settings, while HDAC inhibition may be more critical for therapeutic intervention in established cancers.

Anti-inflammatory and Neuroprotective Pathways

The core mechanisms of Nrf2 activation and HDAC inhibition translate into significant anti-inflammatory and neuroprotective effects. Chronic inflammation and oxidative stress are key drivers of neurodegeneration and are implicated in neurodevelopmental disorders. Sulforaphane counteracts these processes through several interconnected pathways.

It has been shown to inhibit the canonical pro-inflammatory signaling pathway driven by Nuclear Factor kappa-B (NF-κB).[5] In the central nervous system, this translates to a modulation of glial cell activity. Sulforaphane can suppress the activation of microglia, the brain's resident immune cells, reducing their production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (

TNFα), interleukin-1 beta (IL−1β), and interleukin-6 (IL−6).[25]

The antioxidant response driven by Nrf2 activation is synergistic with its anti-inflammatory effects. The reduction of reactive oxygen species by Nrf2-induced enzymes helps to break the vicious cycle where oxidative stress perpetuates NF-κB-driven inflammation.[25] By mitigating both of these pathological drivers, sulforaphane protects neurons from damage and cell death in a variety of preclinical models of neurological disease, including ischemia, neurotoxicity, and Alzheimer's disease.[25]

Pharmacokinetic Profile (ADME)

The absorption, distribution, metabolism, and excretion (ADME) profile of sulforaphane determines its concentration and duration of action at target sites within the body. Its pharmacokinetics are characterized by rapid absorption, tissue distribution, extensive metabolism, and efficient excretion, with evidence of non-linear behavior and a unique metabolic equilibrium that may prolong its biological activity.

Absorption

Sulforaphane is generally well and rapidly absorbed from the gastrointestinal tract following oral administration.[28] In preclinical rat models, the time to reach maximum plasma concentration (

Tmax​) is short, typically occurring within 5 to 30 minutes.[28]

The absolute bioavailability of sulforaphane is high at low doses, reported to be approximately 82% at a dose of 0.5 mg/kg in rats.[28] However, its absorption kinetics appear to be non-linear. As the oral dose increases, bioavailability has been observed to decrease, suggesting that absorption mechanisms or first-pass metabolic pathways may become saturated at higher concentrations.[28] This non-linearity is an important consideration for dose selection in clinical trials.

Distribution

Following absorption, sulforaphane distributes from the plasma into various tissues. Its moderate volume of distribution at steady-state (Vss​ of 2268 mL/kg in rats) indicates that it does not remain confined to the bloodstream but penetrates peripheral compartments.[28] This is consistent with its demonstrated biological effects in organs such as the liver, lungs, prostate, and colon.[22] Notably, studies in rats have shown that sulforaphane tends to accumulate in bladder tissue, a finding that provides a strong rationale for investigating its potential therapeutic role in bladder cancer.[29]

Metabolism

Sulforaphane undergoes rapid and extensive metabolism, primarily through the mercapturic acid pathway.[28] This is a major detoxification route for electrophilic compounds. Upon entering circulation, sulforaphane is quickly conjugated with the endogenous antioxidant glutathione (GSH) in a reaction that can be catalyzed by glutathione S-transferases (GSTs).[20]

This initial SFN-GSH conjugate is then sequentially processed to form sulforaphane-cysteine-glycine, sulforaphane-cysteine, and finally, sulforaphane N-acetylcysteine (SFN-NAC).[28] SFN-NAC is the most stable of these metabolites and represents the primary form of sulforaphane that is ultimately excreted in the urine.[28]

In vitro studies have shown that sulforaphane is metabolically unstable, particularly in plasma, where it is degraded more rapidly than in liver microsomal preparations. This suggests that conjugation with plasma thiols or other plasma-based metabolic processes are significant drivers of its clearance.[28]

A crucial aspect of its metabolism is the reversible nature of the conjugation process. The SFN conjugates, particularly SFN-NAC, can be converted back to the parent, active sulforaphane, establishing a physiological equilibrium.[28] This dynamic interplay has led to the "Prodrug Reservoir" hypothesis: the body effectively creates a circulating pool of SFN conjugates that can release active SFN over time. This reservoir could prolong the biological half-life and duration of action of sulforaphane beyond what would be predicted by measuring the parent compound alone. This also supports the potential development of SFN-NAC itself as a more stable prodrug formulation to improve therapeutic delivery.[28]

Excretion

Sulforaphane and its metabolites are cleared from the body relatively quickly. Total body clearance in rats was measured at 40.7 mL/min/kg.[28] The majority of an administered dose, estimated at 70% to 90%, is eliminated from the body, with the primary route of excretion being renal (via urine).[29] The main excretory products are the metabolites of the mercapturic acid pathway, predominantly SFN-NAC.[28]

Significant inter-individual variability has been observed in the urinary and fecal excretion patterns of sulforaphane metabolites in humans. This variation is thought to be influenced by differences in individual gut microbiome composition, which can affect the initial conversion of glucoraphanin, as well as genetic polymorphisms in metabolic enzymes like GSTs.[15]

Clinical Evidence and Therapeutic Potential

The extensive preclinical data supporting sulforaphane's mechanisms of action have prompted numerous clinical investigations into its therapeutic utility. The most compelling evidence has emerged in the fields of oncology and neurodevelopmental disorders, though its potential applications are broad. The clinical data, however, are not uniformly positive, highlighting the complexities of translating a phytochemical into a reliable therapeutic agent.

Oncology: Chemoprevention and Adjunctive Therapy

In oncology, sulforaphane is primarily positioned as a "green chemopreventive" agent—a compound capable of preventing, blocking, or reversing the early stages of carcinogenesis.[31] Evidence is strongest for its role in early-stage or high-risk settings rather than as a treatment for advanced disease. A summary of key trials is presented in Table 2.

Table 2: Summary of Key Clinical Trials in Oncology

Cancer Type	Study Reference	Patients (Intervention vs. Control)	Intervention (Dose, Formulation)	Duration	Key Outcomes/Findings
Prostate Cancer (Recurrent)	Cipolla B., 2015 32	78 (38 vs. 40)	60 mg/day oral SFN tablets	6 months	SFN significantly lengthened PSA doubling time by 86% compared to placebo.
Prostate Cancer (Early)	Traka M., 2019 32	61 (41 vs. 20)	Broccoli soup with 214 or 492 µmol glucoraphanin once weekly	1 year	Altered gene expression in prostate tissue, affecting pathways related to cancer progression.
Breast Cancer (Benign/DCIS)	Atwell L., 2015 24	54 (27 vs. 27)	224 mg/day glucoraphanin (BroccoMax™)	2-8 weeks	Reduced HDAC activity; trend towards decreased cell proliferation (Ki-67). Well tolerated.
Pancreatic Cancer	(Cited in 32)	N/A	90 mg SFN + 180 mg glucoraphanin per day	1 year	Higher (but not statistically significant) overall survival rate in the SFN group vs. placebo.
Melanoma (Prevention)	NCT07040280 33	(Planned)	Avmacol® Extra Strength tablets	12 months	Phase II trial to evaluate SFN for preventing melanoma in patients with a history of melanoma and atypical nevi.

In prostate cancer, the evidence is encouraging for patients with biochemically recurrent disease. A study administering 60 mg of oral SFN daily demonstrated a significant delay in the rise of Prostate-Specific Antigen (PSA) levels, a key marker of disease progression.[32] In men with early-stage disease, dietary interventions with glucoraphanin-rich broccoli soup have been shown to favorably modulate gene expression profiles within prostate tissue.[32]

In breast cancer, research has focused on women with abnormal mammograms or early-stage ductal carcinoma in situ (DCIS). Supplementation with a broccoli sprout extract was found to be well-tolerated, reduce HDAC activity, and show a trend towards slowing cancer cell growth.[24] These findings support the concept that sulforaphane may help slow the progression of existing tumors in their early phases.[24]

Neurodevelopmental Disorders: Autism Spectrum Disorder (ASD)

The investigation of sulforaphane for Autism Spectrum Disorder (ASD) has produced some of the most striking, yet also most debated, clinical results. The rationale for its use is based on its ability to counteract core biochemical abnormalities associated with ASD, including oxidative stress, mitochondrial dysfunction, and neuroinflammation.[35]

The field was galvanized by a landmark 2014 study published in PNAS. This randomized, double-blind, placebo-controlled trial administered a weight-based dose of sulforaphane (50–150 µmol/day, equivalent to approximately 9–27 mg) from broccoli sprout extract to young men (aged 13–27) with moderate-to-severe ASD for 18 weeks.[35] The results were substantial: participants receiving sulforaphane showed statistically significant improvements in behavior, social interaction, and verbal communication, as measured by the Aberrant Behavior Checklist (ABC) and Social Responsiveness Scale (SRS).[36] The improvements were notable, with a 34% reduction in ABC scores and a 17% reduction in SRS scores compared to placebo. Critically, these gains were reversible, with scores returning toward baseline levels after treatment was discontinued, suggesting a direct pharmacological effect.[35]

However, this promising result has been difficult to replicate, particularly in younger populations. A subsequent high-quality, double-blind, placebo-controlled trial in children with ASD aged 3–7 years found no statistically significant clinical improvement in any of the behavioral outcome measures after 36 weeks of treatment with 50 µmol/day of sulforaphane.[38] Other studies in pediatric cohorts have reported similarly mixed or inconsistent results.[39]

This discrepancy between the positive findings in adolescents and adults and the null findings in young children gives rise to the "Age-Dependent Efficacy Hypothesis." It is plausible that sulforaphane's therapeutic window for ASD is not uniform across the lifespan. The underlying pathophysiology of ASD involves complex neurodevelopmental trajectories. Sulforaphane may be less effective at altering these core developmental pathways in early childhood but more effective at modulating the established biochemical and behavioral symptoms (e.g., oxidative stress, inflammation-driven irritability) present in adolescents and adults. This represents a critical area for future research, requiring trials carefully stratified by age and developmental stage. A summary of these key trials is presented in Table 3.

Table 3: Summary of Key Clinical Trials in Autism Spectrum Disorder

Study Reference	Patient Population (Age)	N (SFN vs. Placebo)	Intervention (Dose, Formulation)	Duration	Outcome Measures	Summary of Results
Singh et al., 2014 35	Young Men (13–27 yrs)	29 vs. 15	50-150 µmol/day (weight-based), Broccoli Sprout Extract	18 weeks	ABC, SRS, CGI-I	Positive: Significant improvements in behavior, social interaction, and verbal communication. Effects were reversible.
(Cited in 38)		Children (3–7 yrs)	(N/A)	50 µmol/day, SFN	36 weeks	ADOS-2, SRS-2, ABC
NCT02909959 41	Young Men (13–30 yrs)	(Planned: 24 vs. 24)	46.5-124 µmol/day (weight-based), Avmacol®	12 weeks	SRS-2, ABC, CGI-I	Trial to assess efficacy in reducing core and associated symptoms of ASD.

Investigational Applications

Beyond oncology and ASD, sulforaphane is being actively investigated for a range of other conditions linked to oxidative stress and inflammation. A completed Phase 2 clinical trial has explored the use of broccoli sprout extract for patients with Type 2 Diabetes [42], and preclinical models suggest it may ameliorate diabetes-associated cognitive impairment.[43] Other areas of active clinical or preclinical investigation include Chronic Obstructive Pulmonary Disease (COPD), Parkinson's Disease, cardiovascular health, and allergic airway disease.[4]

Safety, Tolerability, and Risk Profile

While sulforaphane is a natural compound consumed in the diet, its potent bioactivity necessitates a thorough evaluation of its safety profile, particularly when used in concentrated supplemental forms. The available evidence from human clinical trials and preclinical toxicology studies indicates that sulforaphane is generally well-tolerated at therapeutic doses, but it is not without risks, including specific precautions and a notable potential for drug interactions.

Adverse Events Profile in Human Studies

Across numerous clinical trials, sulforaphane has demonstrated a favorable safety profile.[32] The most frequently reported adverse events are mild to moderate in severity and are predominantly gastrointestinal in nature. These include:

• Gas and bloating [45]
• Stomach upset or heartburn [34]
• Constipation or diarrhea [40]

These side effects are often dose-dependent and can be mitigated by administering sulforaphane with food or by starting with a lower dose and gradually titrating upwards as tolerated.[45] In most controlled trials, the incidence of these mild adverse events was not significantly different between the sulforaphane and placebo groups.[32]

Preclinical Toxicity and Dose-Limiting Effects

Preclinical toxicology studies in animal models have been conducted to establish the upper limits of safety for sulforaphane. These studies indicate that toxicity occurs only at very high doses that are orders of magnitude greater than those used in human clinical trials or provided by typical dietary intake. Evidence of toxicity in rodents has been observed at doses in the range of 150 to 300 mg/kg of body weight.[30] The observed signs of high-dose toxicity include:

• Sedation
• Hypothermia (low body temperature)
• Impaired motor coordination
• Decreased skeletal muscle strength [40]

In vitro studies on cultured neuronal cells have revealed a hormetic, or biphasic, dose-response curve. Low concentrations of sulforaphane (e.g., 2.5 µM) are neuroprotective, whereas higher concentrations (e.g., ≥ 50 µM) can become cytotoxic.[27] This underscores the importance of dose optimization for achieving therapeutic benefit while avoiding potential harm.

Precautions and Special Populations

Caution is advised when considering sulforaphane supplementation for certain populations due to a lack of specific safety data or potential physiological interactions:

• Pregnancy and Breastfeeding: While sulforaphane consumed from whole foods is considered safe, the effects of high-dose supplementation have not been studied in these populations. Therefore, it is recommended to avoid concentrated supplements and adhere to normal dietary intake.[34]
• Thyroid Conditions: Isothiocyanates, as a class, are known as goitrogens, meaning they can interfere with iodine uptake by the thyroid gland. Individuals with pre-existing thyroid conditions, especially hypothyroidism, should consult with a healthcare provider before initiating high-dose sulforaphane supplementation.[45]
• Seizure Disorders: There have been rare case reports of seizures in individuals with a known history of seizure disorders after taking sulforaphane. Although a causal link has not been established, it warrants caution in this population.[34]
• Allergies: Individuals with known allergies to cruciferous vegetables (e.g., broccoli, kale) or sulfur-containing compounds should avoid sulforaphane supplements or use them with extreme caution.[45]

Clinically Significant Drug Interactions

The widespread perception of "natural" compounds as inherently safe can be misleading. Sulforaphane is a potent bioactive molecule with a significant potential to interact with pharmaceutical drugs, a fact that is often overlooked. These interactions can be both metabolic (pharmacokinetic) and pharmacodynamic.

The most significant metabolic interactions stem from sulforaphane's ability to modulate the activity of the cytochrome P450 (CYP450) family of liver enzymes, which are responsible for the metabolism of a vast number of prescription medications. Specifically, sulforaphane has been shown to affect CYP1A2, CYP2E1, and CYP3A4.[34] By inhibiting or inducing these enzymes, sulforaphane can alter the clearance of co-administered drugs, potentially leading to increased toxicity or reduced efficacy. This necessitates a high degree of clinical vigilance, especially for patients on multiple medications or those taking drugs with a narrow therapeutic index.

In addition to metabolic interactions, specific pharmacodynamic interactions have been identified. These are summarized in Table 4.

Table 4: Summary of Potential Drug-Drug Interactions

Interacting Drug/Class	Mechanism of Interaction	Potential Clinical Outcome	Source(s)
Local Anesthetics (e.g., Lidocaine, Benzocaine, Bupivacaine)	Pharmacodynamic	Increased risk or severity of methemoglobinemia	4
Other Drugs (e.g., Meloxicam, Diphenhydramine, Phenol)	Pharmacodynamic	Increased risk or severity of methemoglobinemia	4
Erythropoiesis-Stimulating Agents (e.g., Erythropoietin, Darbepoetin alfa)	Pharmacodynamic	Increased risk or severity of thrombosis	4
CYP1A2, CYP2E1, CYP3A4 Substrates	Metabolic (Enzyme Modulation)	Altered plasma levels of co-administered drugs, leading to potential changes in efficacy and/or toxicity	34
Etrasimod	Pharmacodynamic	Increased risk or severity of immunosuppression	4
Nelarabine	Pharmacodynamic	Increased risk or severity of adverse effects	4

This profile of potential interactions underscores that sulforaphane should be treated as a pharmacologically active agent, not merely as a food component, when used in concentrated forms.

Regulatory Status and Commercial Landscape

Sulforaphane occupies a unique and complex position at the intersection of nutrition, dietary supplements, and pharmaceutical development. This regulatory duality creates a dynamic market landscape with both significant opportunities and considerable challenges related to product quality, efficacy, and consumer safety.

Regulatory Framework: A Nutraceutical in the US and Europe

In most markets, sulforaphane is available to consumers as a nutraceutical or dietary supplement, not as a prescription drug.[12] However, the regulatory oversight for these products differs substantially between the United States and Europe.

• United States: In the U.S., sulforaphane-containing products are regulated by the Food and Drug Administration (FDA) under the framework of the Dietary Supplement Health and Education Act (DSHEA) of 1994.[50] Under DSHEA, dietary supplements are treated as a category of food. Manufacturers are responsible for ensuring the safety of their products but are not required to provide the FDA with evidence of efficacy prior to marketing. They are permitted to make "structure-function" claims (e.g., "supports the body's natural detoxification processes"), but they are prohibited from making claims that their product can diagnose, treat, cure, or prevent any disease.[50] This relatively permissive environment has led to a proliferation of sulforaphane supplements with wide variability in quality, dosage, and bioavailability.
• Europe: The regulatory environment in the European Union is significantly stricter.[50] Products are typically classified as "food supplements," and any health claims made on the label or in marketing materials must be substantiated by a robust portfolio of scientific evidence and receive prior authorization from the European Food Safety Authority (EFSA). This higher evidentiary bar means that fewer explicit health claims can be made, and manufacturers must adhere to stringent quality control regulations to ensure product safety and consistency.[18]

FDA Orphan Drug Designation

In a clear recognition of its therapeutic potential beyond general wellness, a specific formulation of "stabilized sulforaphane" has been granted Orphan Drug Designation by the U.S. FDA.[51] This designation, awarded to Evgen Pharma PLC on August 22, 2016, is for the

"Treatment of subarachnoid hemorrhage".[51]

It is critical to understand the implications of this status. Orphan Drug Designation is a regulatory tool designed to provide incentives (e.g., tax credits, market exclusivity) to encourage the development of drugs for rare diseases (affecting fewer than 200,000 people in the U.S.). However, designation is not the same as approval. As of the latest available data, this specific sulforaphane formulation is "Not FDA Approved for Orphan Indication".[51] This means it is still in the investigational phase and cannot be legally marketed as a treatment.

This situation creates a fascinating regulatory duality. On one hand, the FDA officially recognizes the pharmacological potential of a specific, high-quality sulforaphane formulation for a serious medical condition. On the other hand, the broader market is populated by a wide array of unregulated supplements of varying quality. The eventual success or failure of the orphan drug development path could have profound implications for the entire sulforaphane market, potentially driving a "flight to quality" and forcing supplement manufacturers to adopt more rigorous standards for formulation and clinical validation.

Commercial Supplementation: Dosage and Formulation Considerations

The commercial supplement market for sulforaphane is characterized by a lack of standardization in both dosage and formulation.

• Dosage Variability: There is no official Recommended Daily Intake for sulforaphane.[52] Dosages used in clinical trials have ranged widely, from as low as 9 mg to as high as 60 mg per day.[14] Commercial supplements reflect this variability, with products offering anywhere from 400 micrograms (0.4 mg) to over 20 mg of sulforaphane or its precursor per serving.[53] Based on a synthesis of clinical research, an effective daily dose for activating detoxification and antioxidant pathways is often cited to be in the range of 10–20 mg.[13]
• Formulation is Paramount: As detailed in Section 3, the formulation of a supplement is the single most important factor determining its efficacy. Products that contain only the precursor glucoraphanin without active myrosinase will have very low and unreliable bioavailability.[15] Higher-quality supplements will specify the guaranteed yield of active sulforaphane and will incorporate technologies to ensure this yield, such as co-formulating with active myrosinase or using a stabilized, free form of sulforaphane.[13] This places a significant burden on the consumer and clinician to scrutinize product labels and demand evidence of bioavailability.

Synthesis and Future Directions

Sulforaphane has emerged from the realm of nutritional science to become a compelling therapeutic candidate with well-defined, pleiotropic mechanisms of action. Its dual capacity to activate the master-regulatory Nrf2 pathway and inhibit HDACs provides a strong scientific rationale for its investigation in a wide range of chronic diseases. However, the translation of this preclinical promise into consistent clinical benefit is fraught with challenges that must be addressed through rigorous and strategic future research.

Critical Assessment of Current Evidence and Research Gaps

The existing body of evidence confirms that sulforaphane is a potent bioactive molecule. Its clinical potential is most apparent in the chemoprevention of certain cancers and in the symptomatic management of ASD in specific populations. Yet, the path forward is obstructed by several critical research gaps:

• The Bioavailability and Standardization Gap: The most significant hurdle to the reliable clinical application of sulforaphane is the "Myrosinase Gap." The variability in conversion from the inactive precursor glucoraphanin to active sulforaphane renders much of the existing clinical data difficult to interpret and compare. Many studies fail to adequately characterize the bioavailability of their investigational product, making it impossible to know the true dose of active compound delivered.
• The Dose-Response Gap: The optimal therapeutic dose of sulforaphane for different indications remains largely unknown. Clinical trials have employed a wide range of doses and formulations, and clear dose-response relationships for key clinical endpoints have not been established. Future studies must incorporate robust dose-finding components and link pharmacokinetic profiles to pharmacodynamic outcomes.
• The Clinical Heterogeneity Gap: The inconsistent results observed in clinical trials, most notably in ASD, highlight the need to understand patient-specific factors that influence response. The stark difference in outcomes between adolescent and pediatric ASD trials suggests that age and developmental stage are critical variables. Other factors, such as disease subtype, severity, and genetic polymorphisms (e.g., in GST enzymes), may also play a significant role and need to be investigated through stratified trial designs.

Recommendations for Future Clinical Investigation

To move the field forward and realize the therapeutic potential of sulforaphane, future clinical research should be guided by the following recommendations:

• Pharmacokinetics and Formulation: Head-to-head clinical trials are urgently needed to directly compare the pharmacokinetics and pharmacodynamics of different sulforaphane delivery systems: whole foods (e.g., broccoli sprouts), myrosinase-active supplements, and stabilized free sulforaphane formulations. All future clinical trials, regardless of indication, must use a standardized, well-characterized product with verified bioavailability and must include pharmacokinetic assessments.
• Oncology: Research should focus on large-scale, long-term prevention trials in well-defined high-risk populations (e.g., individuals with a history of melanoma or high-grade prostatic intraepithelial neoplasia). Additionally, trials evaluating sulforaphane as an adjuvant therapy in early-stage cancers, with the goal of reducing recurrence, are warranted.
• Autism Spectrum Disorder: Future trials must be designed to explicitly test the "Age-Dependent Efficacy Hypothesis" by stratifying participants into distinct developmental age groups (e.g., early childhood, adolescence, adulthood). In addition to subjective behavioral scales, these trials should incorporate objective biomarkers of target engagement, such as markers of oxidative stress, inflammation, and Nrf2 pathway activation, to provide a more mechanistic understanding of response or non-response.

Implications for Clinical Practice and Nutraceutical Development

For clinicians, it is important to recognize sulforaphane not as a simple vitamin, but as a potent phytochemical with drug-like activity. This entails an awareness of its favorable but not risk-free safety profile and, critically, its significant potential for drug-drug interactions via CYP450 modulation. When recommending supplementation, clinicians should guide patients toward high-quality products from reputable manufacturers who can provide evidence of bioavailability and active compound yield.

For the nutraceutical industry, the future of sulforaphane as a high-value, evidence-based product lies in overcoming the bioavailability challenge. The market will likely bifurcate, with generic, low-bioavailability glucoraphanin products on one end, and premium, scientifically validated formulations on the other. Companies that invest in pharmaceutical-grade quality control, conduct pharmacokinetic studies on their specific formulations, and sponsor rigorous clinical trials will differentiate themselves and build credibility with both consumers and healthcare professionals. The ongoing development of a stabilized sulforaphane formulation under an FDA Orphan Drug designation represents the pinnacle of this evidence-based approach and will be a critical development to monitor, as its success could elevate the scientific standing of the entire field.

Works cited

1. L-Sulforaphane | CAS 142825-10-3 | Cayman Chemical | Biomol.com, accessed September 17, 2025, https://www.biomol.com/products/chemicals/biochemicals/l-sulforaphane-cay14797-1
2. L-Sulforaphane (CAS 142825-10-3) - Cayman Chemical, accessed September 17, 2025, https://www.caymanchem.com/product/14797/l-sulforaphane
3. Sulforaphane | C6H11NOS2 | CID 5350 - PubChem, accessed September 17, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Sulforaphane
4. Sulforaphane: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 17, 2025, https://go.drugbank.com/drugs/DB12422
5. Sulforaphane | CAS#4478-93-7 - MedKoo Biosciences, accessed September 17, 2025, https://www.medkoo.com/products/5861
6. CAS 142825-10-3 L-Sulforaphane - BOC Sciences, accessed September 17, 2025, https://www.bocsci.com/l-sulforaphane-cas-142825-10-3-item-84008.html
7. pubchem.ncbi.nlm.nih.gov, accessed September 17, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Sulforaphane#:~:text=Sulforaphane%20is%20an%20isothiocyanate%20having,a%20sulfoxide%20and%20an%20isothiocyanate.
8. Getting the Most Out of Your Food - Sulforaphane - Pinnacle Hill Chiropractic, accessed September 17, 2025, https://pinnaclehillchiropractic.com/2021/01/getting-the-most-out-of-your-food-sulforaphane/
9. Sulforaphane: Benefits, Side Effects, and Food Sources - Healthline, accessed September 17, 2025, https://www.healthline.com/nutrition/sulforaphane
10. Food as Medicine: Cruciferous Veggies - Foodbank of Santa Barbara County, accessed September 17, 2025, https://foodbanksbc.org/food-as-medicine-cruciferous-veggies/
11. Definition of sulforaphane - NCI Drug Dictionary, accessed September 17, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sulforaphane
12. Anticancer properties of sulforaphane: current insights at the molecular level - PMC, accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10313060/
13. How Much Sulforaphane Per Day Is Optimal? Here's What Science Says, accessed September 17, 2025, https://brocshot.com/blogs/post/how-much-sulforaphane-per-day
14. Efficacy and tolerability of sulforaphane in the therapeutic management of cancers: a systematic review of randomized controlled trials - Frontiers, accessed September 17, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1251895/full
15. Brassica oleracea Broccoli Group: Pharmacokinetics (ADME) - American Botanical Council, accessed September 17, 2025, https://www.herbalgram.org/resources/herbmedpro/herb-list/brassica-oleracea-broccoli-group?subCat=Pharmacokinetics%20%28ADME%29
16. Absorption and chemopreventive targets of sulforaphane in humans ..., accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4394840/
17. Sulforaphane: Its “Coming of Age” as a Clinically Relevant Nutraceutical in the Prevention and Treatment of Chronic Disease - PMC, accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6815645/
18. Prostaphane Sulforaphane - Be Active For Your Prostate, accessed September 17, 2025, https://www.veru.ie/about-product
19. Sulforaphane and Other Nutrigenomic Nrf2 Activators: Can the Clinician's Expectation Be Matched by the Reality? - PMC, accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4736808/
20. Review Article Sulforaphane Protects against Cardiovascular Disease via Nrf2 Activation - Semantic Scholar, accessed September 17, 2025, https://pdfs.semanticscholar.org/33ce/f77a5a6fd752145d00b2ac310bfdb4175b26.pdf
21. The effect of sulforaphane on histone deacetylase activity in keratinocytes: differences between in vitro and in vivo analyses - PMC, accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4394046/
22. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice - PubMed, accessed September 17, 2025, https://pubmed.ncbi.nlm.nih.gov/16407454/
23. Sulforaphane destabilizes the androgen receptor in prostate cancer ..., accessed September 17, 2025, https://www.pnas.org/doi/10.1073/pnas.0908908106
24. Sulforaphane slows cancer cell growth in early-stage breast cancer - Synergies, accessed September 17, 2025, https://synergies.oregonstate.edu/2016/sulforaphane-slows-cancer-cell-growth-in-early-stage-breast-cancer/
25. Broccoli for the brain: a review of the neuroprotective mechanisms of ..., accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12271217/
26. Sulforaphane - Comprehensive protection of brain, gut, and cancer prevention, accessed September 17, 2025, https://longevity-protocols.com/en/knowledge-base/interventions/positive/sulforaphane/
27. Sulforaphane Protects Brain Cells from... - ERA: Education & Research Archive - University of Alberta, accessed September 17, 2025, https://era.library.ualberta.ca/items/8da8a3c3-d70c-4446-ba59-725b16b0bd99
28. Comparison of Pharmacokinetics and Anti-Pulmonary Fibrosis ..., accessed September 17, 2025, https://www.mdpi.com/1999-4923/13/7/958
29. Sulforaphane and bladder cancer: a potential novel antitumor compound - Frontiers, accessed September 17, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1254236/full
30. Determining the optimal dose and source of sulforaphane poses challenges. Digest, accessed September 17, 2025, https://www.foundmyfitness.com/stories/29donw/determining_the_optimal_dose_and_source_of_sulforaphane_poses_challenges
31. Sulforaphane: An emergent anti-cancer stem cell agent - Frontiers, accessed September 17, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1089115/full
32. Efficacy and tolerability of sulforaphane in the therapeutic ..., accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10710291/
33. Study Details | NCT07040280 | Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma | ClinicalTrials.gov, accessed September 17, 2025, https://clinicaltrials.gov/study/NCT07040280
34. SULFORAPHANE: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews - WebMD, accessed September 17, 2025, https://www.webmd.com/vitamins/ai/ingredientmono-1070/sulforaphane
35. Sulforaphane treatment of autism spectrum disorder (ASD) - PMC, accessed September 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4217462/
36. Sulforaphane treatment of autism spectrum disorder (ASD) - PNAS, accessed September 17, 2025, https://www.pnas.org/doi/abs/10.1073/pnas.1416940111
37. Sulforaphane treatment of autism spectrum disorder (ASD) - PNAS, accessed September 17, 2025, https://www.pnas.org/doi/10.1073/pnas.1416940111
38. Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study - MDPI, accessed September 17, 2025, https://www.mdpi.com/2072-6643/15/3/718
39. Therapeutic efficacy of sulforaphane in autism spectrum disorders and its association with gut microbiota: animal model and human longitudinal studies - Frontiers, accessed September 17, 2025, https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1294057/full
40. Sulforaphane: Benefits, Safety, and Nutrition - Verywell Health, accessed September 17, 2025, https://www.verywellhealth.com/sulforaphane-5083128
41. Study Details | NCT02909959 | Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder | ClinicalTrials.gov, accessed September 17, 2025, https://clinicaltrials.gov/study/NCT02909959
42. Sulforaphane Completed Phase 2 Trials for Diabetes Mellitus, Noninsulin Dependent Treatment | DrugBank Online, accessed September 17, 2025, https://go.drugbank.com/drugs/DB12422/clinical_trials?conditions=DBCOND0043945&phase=2&purpose=treatment&status=completed
43. Activation of the Nrf2 Pathway by Sulforaphane Improves Hypoglycaemia-Induced Cognitive Impairment in a Rodent Model of Type 1 Diabetes - MDPI, accessed September 17, 2025, https://www.mdpi.com/2076-3921/14/3/308
44. Sulforaphane's therapeutic uses | Research Starters - EBSCO, accessed September 17, 2025, https://www.ebsco.com/research-starters/health-and-medicine/sulforaphanes-therapeutic-uses
45. Side Effects of Sulforaphane: Myths, Facts, and Safety Tips - Broc Shot, accessed September 17, 2025, https://brocshot.com/blogs/post/sulforaphane-side-effects
46. Can Sulforaphane Treatment Of Autism Make A Difference? - Kids Club ABA, accessed September 17, 2025, https://kidsclubaba.com/can-sulforaphane-treatment-of-autism-make-a-difference/
47. Sulforaphane: Benefits, Uses, Side Effects, and More - Health, accessed September 17, 2025, https://www.health.com/sulforaphane-benefits-8658448
48. Sulforaphane (SFA) protects neuronal cells from oxygen & glucose deprivation (OGD) | PLOS One - Research journals, accessed September 17, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0248777
49. Are There Any Dangerous Side Effects of Sulforaphane? - Longevity.Technology, accessed September 17, 2025, https://longevity.technology/clinics/are-there-any-dangerous-side-effects-of-sulforaphane/
50. Navigating the Regulatory Landscape for Nutraceuticals in the US ..., accessed September 17, 2025, https://jafconsulting.com/blog/navigating-the-regulatory-landscape-for-nutraceuticals-in-the-us-and-europe/
51. Search Orphan Drug Designations and Approvals - accessdata.fda ..., accessed September 17, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=530616
52. Sulforaphane Benefits: The Secret to Broccoli's Superfood Status - Dr. Axe, accessed September 17, 2025, https://draxe.com/nutrition/sulforaphane-benefits/
53. Sulforaphane - Broccoli Extract Powder - NaMaximum, accessed September 17, 2025, https://www.namaximum.com/sulforaphane-broccoli-extract-powder
54. Broccoli Sprout Extract (Sulforaphane) 400mcg by Swanson - HSN, accessed September 17, 2025, https://www.hsnstore.eu/brands/swanson/sulforaphane-400mcg